|Anti-mCTLA4-mIgG2a InvivoFit™||Unit size||Cat. code||Docs||Qty||Price|
9D9-derived mouse monoclonal antibody against murine CTLA-4
Recombinant mouse mAb against murine CTLA-4
Anti-mCTLA4-mIgG2a InvivoFit™ is a mouse anti-mouse monoclonal antibody (mAb) featuring the variable region of the previously described anti-mCTLA-4 9D9 mAb  and a murine IgG2a constant region. The 9D9 mAb has a sequence that is 100% murine (constant and variable regions), ensuring minimal immunogenicity upon repeated injections into mice. This mAb targets murine cytotoxic T-lymphocyte-associated protein 4 (mCTLA-4) and blocks CTLA4-mediated negative signals downregulating T cell activation. Thus, anti-mCTLA-4 mAb unleashes T cell activity [1, 2].
Notably, the 9D9 mAb, along with most commercially available anti-mCTLA4 mAbs feature the IgG2b isotype which displays low antitumor activity in vivo . To overcome this issue, Anti-mCTLA4-mIgG2a InvivoFit™ was generated by recombinant technology and features the murine IgG2a isotype, which mediates potent cytotoxic functions. Anti-mCTLA4-mIgG2a is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies.
Anti-mCTLA4-mIgG2a InvivoFit™ is specifically designed for in vivo studies in mice:
- Sequence is 100% murine
- Features the IgG2a isotype (associated with high antitumor activity)
- Guaranteed sterile, endotoxin level: 1 EU/mg
- Suitable for parenteral delivery in mice (azide-free)
- Low aggregation, < 5%
Anti-mCTLA4-mIgG2a InvivoFit™ is produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with protein A. Its binding to mCTLA-4 is validated using ELISA.
1. Selby MJ. et al., 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 1(1):32-42.
2. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
ELISA binding of Anti-mCTLA4-mIgG2a InvivoFit™ to recombinant murine CTLA-4.
A dilution series of Anti-mCTLA4-mIgG2a InvivoFit™ and anti-mCTLA4 (9D9 clone) was used for the detection of coated mCTLA-4 antigen at 5 µg/ml. Detection of bound antibody was performed using an HRP‑conjugated anti‑murine κ-light chain secondary antibody. HRP activity was assessed by a colorimetric assay using Tetramethylbenzidine (TMB) substrate. Optical density was measured at 490 nm. Data are shown as percentage absorbance.
Specificity: Targets cells expressing murine CTLA-4
Formulation: Lyophilized from 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose
Clonality: Monoclonal antibody
Isotype: Murine IgG2a
Source: CHO cells
Purity: Purified by affinity chromatography with protein A
Tested application: ELISA
- Binding confirmed using ELISA
- The complete sequence of this antibody has been verified
- < 5% aggregates (confirmed by size exclusion chromatography)
- Guaranteed sterile and <1 EU/mg (determined by the LAL assay)
Anti-mCTLA4-mIgG2a InvivoFit™ is provided sterile, endotoxin-free, azide-free and lyophilized.
This product is available in two pack sizes:
- mctla4-mab10-1: 1 mg
- mctla4-mab10-10: 10 mg
Product is shipped at room temperature.
Store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year
Avoid repeated freeze-thaw cycles.Back to the top
The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152) is an inhibitory receptor expressed on activated T lymphocytes. T-cell activation requires two signals. Signal 1 is delivered upon interaction of the T cell receptor (TCR) with antigenic peptides bound to major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). Signal 2 is delivered upon interaction of the co-stimulatory receptor CD28 with the B7 family ligands, B7-1 (CD80) and B7-2 (CD86), on APCs.
CTLA-4 is an immune checkpoint molecule upregulated upon T cell activation. It exerts competitive binding to CD28 ligands, thereby preventing T-cell overstimulation. CTLA-4 blockade with monoclonal antibodies (mAbs) has been used to treat patients with metastatic melanoma.